Tocilizumab in COVID‐19 interstitial pneumonia

Pomponio, Giovanni; Ferrarini, Alessia; Bonifazi, Martina; Moretti, Marco; Salvi, Aldo; Giacometti, Andrea; Tavio, Marcello; Titolo, Giancarlo; Morbidoni, Laura; Frausini, Gabriele; Onesta, Maicol; Amico, Donatella; Rocchi, Marco; Menzo, Stefano; Zuccatosta, Lina; Mei, Federico; Menditto, Vincenzo Giannicola; Svegliati, Silvia; Donati, Abele; D'Errico, M M; Pavani, Marianna; Gabrielli, Armando

doi:10.1111/joim.13231

Cited by 13 publications

(12 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, non-specific immune-regulatory strategies, such as injection of systemic glucocorticosteroids, intravenous immunoglobulins (IVIG), and convalescent serum therapy can also be administered. Pilot studies have shown the life-saving efficacy of IL-6-blocking monoclonal antibodies and reducing the hospitalization period in severe COVID-19 patients with ARDS (61) and several clinical trials are evaluating the safety and efficacy of IL-6 blocking agents to repress the hyperinflammatory condition in hospitalized COVID-19 patients, which are described in Table 1 . Here, we discuss different methods for inhibiting the IL-6 pathway at different stages based on recently published data and clinical trials to develop bench-to-bedside guidance to improve the clinical outcome of the patients.…”

Section: Inhibition Of Il-6 In Covid-19mentioning

confidence: 99%

An updated overview of recent advances, challenges, and clinical considerations of IL-6 signaling blockade in severe coronavirus disease 2019 (COVID-19)

Elahi

Karami

Heidary

et al. 2022

International Immunopharmacology

View full text Add to dashboard Cite

show abstract

Section: Inhibition Of Il-6 In Covid-19mentioning

confidence: 99%

An updated overview of recent advances, challenges, and clinical considerations of IL-6 signaling blockade in severe coronavirus disease 2019 (COVID-19)

Elahi

Karami

Heidary

et al. 2022

International Immunopharmacology

View full text Add to dashboard Cite

show abstract

“…CoV-2 pandemic, IL-6 blockade using monoclonal antibodies was investigated with potential benefits described in several observational or cohort studies [105,127,131,[158][159][160][161]. However, some contrasting data from RCTs with the IL-6 R blocker tocilizumab have raised questions on the real usefulness of these drugs and posed some questions about the real role played by IL-6 in severe COVID-19 [10,139,140,142,143,162,163].…”

Section: Expert Opinionmentioning

confidence: 99%

The role of IL-6 and IL-6 blockade in COVID-19

Potere

Batticciotto

Vecchiè³

et al. 2021

Expert Review of Clinical Immunology

View full text Add to dashboard Cite

Introduction: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) induces a dysregulated hyperinflammatory response. Areas covered: Authors review evidence on IL-6 and IL-6 blockade in coronavirus disease 2019 (COVID-19) and discuss the pathophysiological and prognostic roles of this cytokine and the clinical impact of pharmacological blockade of IL-6 . The material includes original articles and reviews published from March 2020 to March 2021 and searched on PubMed, medRxiv, and bioRxiv. Expert opinion: IL-6 is one of the most prominent pro-inflammatory cytokines. Increased levels are recorded in COVID-19 patients, especially those with severe-to-critical disease. Evidence is accumulating on the relevance of IL-6 as a prognostic marker in COVID-19. Since IL-6 is a druggable target for several inflammatory diseases, pharmacological blockers of the IL-6 signaling pathway were repurposed to blunt the abnormal SARS-CoV-2-induced cytokine release. Data are limited to few randomized controlled trials that reported encouraging, though not conclusive, results, indicating the usefulness of IL-6 blockade early in the course of the disease in patients with hyperinflammation and no or limited organ damage. Further research is warranted to explore the role of IL-6 in different COVID-19 phenotypes and identify subgroups of patients who may mostly benefit from IL-6 pathway inhibition.

show abstract

“…Recently, we demonstrated that serum levels of microRNAs involved in the modulation of inflammation ( Olivieri et al, 2021 , Olivieri et al, 2013 ), were associated with the clinical response to anti-IL-6 receptor therapy in a sample of COVID-19 patients ( Pomponio et al, 2021 , Sabbatinelli et al, 2021 ).…”

Section: Introductionmentioning

confidence: 99%

Circulating miR-320b and miR-483-5p levels are associated with COVID-19 in-hospital mortality

Giuliani

Matacchione

Ramini

et al. 2022

Mechanisms of Ageing and Development

View full text Add to dashboard Cite

The stratification of mortality risk in COVID-19 patients remains extremely challenging for physicians, especially in older patients. Innovative minimally invasive molecular biomarkers are needed to improve the prediction of mortality risk and better customize patient management. In this study, aimed at identifying circulating miRNAs associated with the risk of COVID-19 in-hospital mortality, we analyzed serum samples of 12 COVID-19 patients by small RNA-seq and validated the findings in an independent cohort of 116 COVID-19 patients by qRT-PCR. Thirty-four significantly deregulated miRNAs, 25 downregulated and 9 upregulated in deceased COVID-19 patients compared to survivors, were identified in the discovery cohort. Based on the highest fold-changes and on the highest expression levels, 5 of these 34 miRNAs were selected for the analysis in the validation cohort. MiR-320b and miR-483-5p were confirmed to be significantly hyper-expressed in deceased patients compared to survived ones. Kaplan-Meier and Cox regression models, adjusted for relevant confounders, confirmed that patients with the 20% highest miR-320b and miR-483-5p serum levels had three-fold increased risk to die during in-hospital stay for COVID-19. In conclusion, high levels of circulating miR-320b and miR-483-5p can be useful as minimally invasive biomarkers to stratify older COVID-19 patients with an increased risk of in-hospital mortality.

show abstract

Tocilizumab in COVID‐19 interstitial pneumonia

Cited by 13 publications

References 23 publications

An updated overview of recent advances, challenges, and clinical considerations of IL-6 signaling blockade in severe coronavirus disease 2019 (COVID-19)

An updated overview of recent advances, challenges, and clinical considerations of IL-6 signaling blockade in severe coronavirus disease 2019 (COVID-19)

The role of IL-6 and IL-6 blockade in COVID-19

Circulating miR-320b and miR-483-5p levels are associated with COVID-19 in-hospital mortality

Contact Info

Product

Resources

About